On a late Thursday evening, Celera Corporation (NASDAQ:CRA) and Medical Therapies Limited have announced that they have entered an exclusive license agreement for the use of Medical Therapies’ midkine patent portfolio for the development of novel lung cancer diagnostics. According to the license agreement, Celera will be able to use the Medical Therapies’ midkine patents for the commercialization and development of diagnostic products to address a range of lung cancer related applications which includes risk assessment, differentiation, prognosis, early detection system, disease progression, response to treatment and monitoring of reoccurrence. Celera Corporation and Medical Therapies Limited both are happy about the intellectual property agreement.

Celera Corporation is one of the upcoming healthcare companies that handles personalized disease management products and services and looks after three main segments which

...

BEVERLY, Mass., Oct. 19, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that data recently presented by the Company at the American Association for Cancer Research (AACR) along with other data developed by the Company indicate that Kevetrin is selectively targeting very specific anti-tumor pathways, such as AKT and p38 MAP kinase. The data presented at the AACR showed that Kevetrin was less cytotoxic than paclitaxel, cisplatin and 5FU while having better anti-tumor activity in two multi-drug resistant lung cancer cell lines. This indicates that Kevetrin is not acting primarily as a cytotoxic agent but may be targeting specific components of the signal transduction pathway, such as AKT and p38 MAP kinase. The Company is continuing to explore other potential targets.

Other data developed by the Company indicate that Kevetrin has potent anti-tumor activity in one cell line (MDA-MB–231) despite only partially inhibiting AKT in that cell line.

...

Kevetrin(TM) Shows Excellent Activity in Animal Models of Drug Resistant Lung Cancer With Less Cytotoxicity Than Paclitaxel

Cellceutix of Beverly, MA, to Pursue Development for Drug-Resistant Lung Cancer

BEVERLY, Mass., Oct. 13, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that it presented a poster and its Chief Scientific Officer, Dr. Krishna Menon, was one of only four individuals selected to participate in an expert panel discussion of the abstract at the American Association for Cancer Research (AACR) meeting “Frontiers in Basic Cancer Research” in Boston, MA on October 10, 2009. The Company’s poster describes in vitro and in vivo research on its lead compound, Kevetrin(TM), which is being developed for drug resistant cancers. The three day AACR meeting featured presentations on the latest advances in basic cancer research from around the world. The AACR issued a press release on October 10, 2009 which featured the abstract submitted

...

Yesterday, shares of MannKind Corporation (MNKD) lost more than 30% following the disappointing news about the company’s proposed partnership deal for Afresa, its inhaled insulin product. MannKind stated, in a filing with the SEC, that the company will not be able to enter into a deal by year end, as was earlier expected. Although the company announced that it has made some progress in the partnership deal, we believe that any potential partner would wait for US Food and Drug Administration (FDA) approval to come before entering into any agreement. MannKind is seeking FDA approval of Afresa for the treatment of type I and type II diabetes. With a Prescription Drug User Fee Act (PDUFA) date of January 16, 2010 for Afresa, we believe a partnership deal is not likely before that. The approval of Afresa is significant not only from the company’s perspective but ...

Yesterday, patient enrollment (1200) for a phase III trial of ASA404, jointly developed by Novartis (NVS) and Antisoma for the treatment of non small-cell lung cancer (NSCLC) was completed. Novartis is conducting the trial as the development and commercialization partner (for ASA404) of Antisoma. The trial will be conducted to test the effectiveness of the drug as a first-line treatment for squamous and non-squamous NSCLC with results due in 2010 or early 2011. The company expects to file for approval in 2011 if the trial results are positive. In addition to this, Novartis will be conducting another study of the drug in previously treated patients. Lung cancer kills 1.3 million people a year and is one of the leading causes of cancer death across the world. NSCLC accounting for about 87% of all lung cancer patients is one of the leading causes of death. Survival rates ...

Power3 Medical Products, Inc.

(Public, OTC:PWRM)

The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Michael Sklar. He has been studying the markets for several years now with a focus in undiscovered Bio-Pharm companies.

About

Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company

...

Yesterday, Abbott Laboratories (ABT) signed a deal with Pfizer Inc. (PFE) for developing a test to identify patients who are likely to benefit from the latter’s lung-cancer drug. Pfizer’s PF-02341066 is a novel diagnostic agent that selectively targets certain genes implicated in the progress of many cancers.

The therapy can be applied only when a particular genetic translocation (rearrangement) that is found in non-small cell lung cancer (NSCLC) tumors and several other cancers but not in normal cells should be detected. Abbott’s molecular diagnostic test will screen NSCLC tumors for the presence of the gene rearrangements.

The test will determine a patient's genetic status and will be used in patient selection for Pfizer’s clinical trials in future. NSCLC is the most common type of lung cancer and usually grows and spreads more slowly than small cell lung cancer.

Last month, Abbott entered into a similar agreement with

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Friday August 28, 2009

PennyOmega.com Stock Report!

**************************************************************

The Farmers National Bank of Emlenton, the subsidiary operating bank of Emclaire Financial Corp. (OTCBB: EMCF), announced today that the Bank completed its acquisition of the full-service branch office of National City Bank (”National City”), now a part of The PNC Financial Services Group, Inc. (NYSE: PNC), located in Titusville, Pennsylvania. The office will open for full service as a Farmers National Bank office on Monday, August 31, 2009.

Seamless Corporation (OTCBB: SMWF) announced today that it and one of America’s favorite product promoters, Dr. Gadget, further solidified their relationship by Seamless’ acquisition of www.gadgetenterprises.com, an eCommerce website. Terms

...

We are pleased to hear that the US Food and Drug Administration (FDA) accepted and filed for review Cell Therapeutics’ (CTIC) New Drug Application (NDA). The company is seeking FDA approval (NDA filed in June 2009) for pixantrone for the treatment of relapsed and refractory non-Hodgkin’s lymphoma (NHL). Though an action date is yet to be published, the company expects the FDA to take a final decision regarding the review status by Sept 4.

Earlier in June, Cell Therapeutics presented encouraging results from a phase III trial of pixantrone. Although the efficacy data for pixantrone were encouraging, we are concerned about its side effects. While, neutropenia was 41.2% for pixantrone versus 19.4% for comparator, leukopenia was 23.5% for pixantrone versus 4.5% for comparator.

Although the grade 3, 4 cardiac disorder was similar among the two treatment groups (1.5% vs. 1.5%), there was a higher incidence of serious cardiac disorders in patients

...

Biomoda, Inc.

(Public, OTC:BMOD)

StocksHaven Investments profiles one of the most promising up and coming small cap biotech companies, Biomoda Inc, which has established a medical breakthrough for early lung cancer detection. It is a development-stage company. The Company is an invitro diagnostics company that develops assays, or tests, to detect cancer. These assays are performed in clinical reference laboratories using body-fluid samples. This technology is based on a licensed patent from Los Alamos National Laboratories. The technology is based on a molecule that has an affinity to bind with cancer cells and it fluoresces red under ultra violet light. It is a porphyrin molecule. This technology works with a range of cell types. The Company is in the process of developing a line of assays for a variety of cancers based on adaptations of this technology. Biomoda’s first product

...